Key result
Diabetes and other major comorbidities linked to ~38% higher care costs in heart failure patients.
Why the study?
Identifying heart failure patients most likely to suffer poor outcomes and incur higher costs is essential for targeted interventions and resource allocation.
Cohort (n=4,696)
No
Effect estimate: 37.8% increase (95% CI 22.5% to 53.0%)
Comorbidities significantly drive up the cost of care in heart failure patients, highlighting the need to account for competing risks like mortality when analyzing healthcare costs.
Comorbidities like diabetes and depression were tied to higher HF costs; leaves open whether targeting them improves value or outcomes.
BACKGROUND: Identifying heart failure patients most likely to suffer poor outcomes is an essential part of delivering interventions to those most likely to benefit. We sought a comprehensive account of heart failure events and their cumulative economic burden by examining patient characteristics that predict increased cost or poor outcomes. METHODS: We collected electronic medical data from members of a large HMO who had a heart failure diagnosis and an echocardiogram from 1999-2004, and followed them for one year. We examined the role of demographics, clinical and laboratory findings, comorbid disease and whether the heart failure was incident, as well as mortality. We used regression methods appropriate for censored cost data. RESULTS: Of the 4,696 patients, 8% were incident. Several diseases were associated with significantly higher and economically relevant cost changes, including atrial fibrillation (15% higher), coronary artery disease (14% higher), chronic lung disease (29% higher), depression (36% higher), diabetes (38% higher) and hyperlipidemia (21% higher). Some factors were associated with costs in a counterintuitive fashion (i.e. lower costs in the presence of the factor) including age, ejection fraction and anemia. But anemia and ejection fraction were also associated with a higher death rate. CONCLUSIONS: Close control of factors that are independently associated with higher cost or poor outcomes may be important for disease management. Analysis of costs in a disease like heart failure that has a high death rate underscores the need for economic methods to consider how mortality should best be considered in costing studies.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2012) conducted a cohort in Heart failure (n=4,696). Diabetes (as a representative comorbidity) vs. No diabetes was evaluated on Total monthly cost of care (relative percent change) (37.8% increase, 95% CI 22.5% to 53.0%). Several comorbid conditions, including diabetes (38% higher), depression (36% higher), and chronic lung disease (29% higher), were independently associated with significantly higher costs of care in heart failure patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: